You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新股消息 | 艾迪康醫學檢驗中心據悉委任銀行安排香港IPO
uSMART友信智投 08-21 13:21
據彭博報道,艾迪康醫學檢驗中心據悉委任銀行安排香港IPO,或籌資約4億美元,最快明年在香港上市。
艾迪康:醫學檢驗四巨頭之一
據瞭解,艾迪康是醫學檢驗四巨頭中唯一未上市企業
已上市的三巨頭,二級市場表現亮眼:
金域醫學上市3年,累計漲幅高達約900%
迪安診斷上市9年,累計漲幅高達約1040%
達安基因上市16年,累計漲幅高達約3129%
艾迪康醫學檢驗中心有限公司成立於2004年1月8日,是全國連鎖經營的獨立醫學實驗室,已在全國設立了20餘家醫學實驗室。公司採用歐美獨立實驗室的先進管理體系,引進國際高端質量標準,與全球醫學檢驗同行廣泛開展合作交流,提供卓越的醫學檢驗、臨牀試驗、科研服務、健康管理及病理會診服務。
目前,艾迪康擁有臨牀、病理、生殖遺傳、基因檢測、臨牀試驗5大中心實驗室和研發中心,下設20多個專業臨牀實驗室,提供2000餘項檢測項目,與全國上萬家醫療機構建立了合作,可每天爲10萬人以上就近提供統一、嚴謹的檢驗報告。
公開資料顯示,中國的第三方醫學檢驗市場中約有500家左右的獨立醫學實驗室,從市場份額來看,前四名依次爲金域、迪安、艾迪康、達安,其中,艾迪康佔17%。
凱雷投資集團、美年大健康入股
2018年的公開報道顯示,全球另類資產管理公司凱雷投資集團(納斯達克股票代碼:CG)聯手美年大健康產業控股股份有限公司,共同入股中國第三方獨立醫學檢驗機構艾迪康醫學檢驗中心有限公司。凱雷已於投資後成爲艾迪康的第一大股東。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account